AZURITY PHARMACEUTICALS, INC. ANNOUNCES U.S. AVAILABILITY OF ZONISADE™ (zonisamide oral suspension)
MEDIA ALERT: WOBURN, MA, October 12, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific needs of overlooked patients, announced that starting October 17, 2022, ZONISADE™ (zonisamide oral suspension), 100 mg/5 mL will be available in U.S. retail pharmacies as an adjunctive therapy for the treatment of partial seizures in adults and pediatric patients aged 16 years and older. ZONISADE™ is the first and only FDA- approved oral liquid formulation of zonisamide and also the only alternative formulation to solid oral doses of zonisamide.
“Despite many advancements in epilepsy research and management over the last decade, unmet treatment needs continue to remain for epilepsy patients suffering from partial-onset seizures,” said Evan Scullin, M.D., Chief Medical Officer of Azurity Pharmaceuticals. “With the introduction of ZONISADE™, epilepsy patients aged 16 years and older with partial seizures living in the U.S. now have access to an oral liquid zonisamide formulation that may aid in the administration and management of this complex brain disorder.”
An estimated 65 million people have epilepsy globally, and 1 in 26 people will develop epilepsy in the United States.1,2 Epilepsy can also present comorbidities and complications such as learning disabilities, autism, anxiety, or depression, contributing to the burden on patients and their families in the management of the disorder.3
“The epilepsy patient and provider community’s treatment needs are widespread and unique, requiring continuous advancements in treatment,” said Michael C. Smith, M.D., Director, Rush Epilepsy Center, and Professor, Department of Neurological Sciences, Rush University Medical Center. “The oral liquid formulation offered with ZONISADE™ may help the significant number of patients who have difficulty swallowing and could offer prescribing physicians greater flexibility in meeting patient needs.”
Please see Important Safety Information and Full Prescribing Information for ZONISADE™. For more information about ZONISADE™ or patient assistance, please visit ZONISADE.com and AzuritySolutions.com.
For Media Inquiries:
Media@azurity.com
1Mehndiratta, M. M., & Wadhai, S. A. (2015). International Epilepsy Day – A day notified for global public education & awareness. The Indian journal of medical research, 141(2), 143–144.
2Epilepsy Foundation. Who can get epilepsy?. Retrieved June 15, 2022, from https://www.epilepsy.com/what-is-epilepsy/understanding-seizures/who-gets-epilepsy
3Seidenberg, M., Pulsipher, D. T., & Hermann, B. (2009). Association of epilepsy and comorbid conditions. Future neurology, 4(5), 663–668.
PP-ZON-US-0040
